EP 4358999 A1 20240501 - MVA-BASED VACCINE EXPRESSING A PREFUSION-STABILIZED SARS-COV-2 S PROTEIN
Title (en)
MVA-BASED VACCINE EXPRESSING A PREFUSION-STABILIZED SARS-COV-2 S PROTEIN
Title (de)
MVA-BASIERTER IMPFSTOFF ZUR EXPRESSION EINES PRÄFUSIONSSTABILISIERTEN SARS-COV-2S-PROTEINS
Title (fr)
VACCIN À BASE DE MVA EXPRIMANT UNE PROTÉINE S DU SARS-COV-2 STABILISÉE PAR PRÉFUSION
Publication
Application
Priority
- EP 21382557 A 20210623
- EP 21383245 A 20211231
- EP 2022067271 W 20220623
Abstract (en)
[origin: WO2022269003A1] The present invention is directed to a vaccine composition comprising an immunologically effective amount of a modified vaccinia virus Ankara (MVA) vector comprising at least one nucleic acid encoding the spike (S) protein, or a fragment of said S protein comprising at least one epitope, of at least one SARS-CoV-2 variant, wherein said S protein or fragment thereof, comprises at least the substitutions R682G, R683S, R685S, A942P, K986P and V987P, and wherein the MVA vector regulates the expression of the nucleic acid encoding the S protein, or the fragment thereof. The present invention also relates to combination of vaccines and uses thereof.
IPC 8 full level
A61K 39/12 (2006.01); A61K 39/215 (2006.01); A61K 39/285 (2006.01); A61P 31/14 (2006.01); C07K 14/005 (2006.01); C12N 15/00 (2006.01)
CPC (source: EP)
A61K 39/12 (2013.01); A61K 39/215 (2013.01); A61K 39/285 (2013.01); A61P 31/14 (2018.01); C07K 14/005 (2013.01); C12N 2710/20022 (2013.01); C12N 2710/20034 (2013.01); C12N 2710/24143 (2013.01)
Designated contracting state (EPC)
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated extension state (EPC)
BA ME
Designated validation state (EPC)
KH MA MD TN
DOCDB simple family (publication)
DOCDB simple family (application)
EP 2022067271 W 20220623; EP 22737464 A 20220623